Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of the Sources of Strength Peer Leader Program on Suicide Attempt Rates in 40 High Schools: A Cluster Randomized Controlled Trial.

School mental health·2026
Same author

A tool to evaluate the integration of implementation science methods in a research project: The Dissemination and Implementation Research Capability Self Survey (DIRC-SS).

Journal of clinical and translational science·2026
Same author

Research Support Networks for Substance Use Translational Research: A Qualitative Evaluation of the HEAL Data to Action (HD2A) Program.

Research square·2026
Same author

Validation of the Observational Assessment Tool for Tailoring (OATT).

Prevention science : the official journal of the Society for Prevention Research·2026
Same author

Disparities in the Treatment Engagement Cascade of Collaborative Care for Depression in a Pragmatic Implementation Study.

Psychiatric services (Washington, D.C.)·2026
Same author

What scientific inferences can be made with randomized implementation rollout trials.

Implementation science : IS·2025
Same journal

A Drug-Environment Interaction Between PM<sub>2</sub> <sub>.5</sub> Concentration and Corticosteroid Use on Cardiovascular and Thromboembolic Events in Older Adults.

Pharmacoepidemiology and drug safety·2026
Same journal

Association Between Socioeconomic Conditions and Biologic Prescriptions for Inflammatory Bowel Diseases in the Brazilian Public Healthcare System: An Ecological Study.

Pharmacoepidemiology and drug safety·2026
Same journal

Effectiveness of Metformin in Preventing Colorectal Cancer Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation.

Pharmacoepidemiology and drug safety·2026
Same journal

Trends in Pharmacist-Prescribed Dispensing Records of HIV Pre-Exposure (2020-2025) and Post-Exposure Prophylaxis (2020-2024) in Brazil: A Time Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

French Consumption of Methylphenidate in Primary Care From 2016 to 2023, Impact of Prescribing Policy Changes-A Time-Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study.

Pharmacoepidemiology and drug safety·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Gabapentin and suicide attempts.

Robert D Gibbons1, Kwan Hur, C Hendricks Brown

  • 1Center for Health Statistics, University of Illinois at Chicago, Chicago, IL 60612, USA. rdgib@uic.edu

Pharmacoepidemiology and Drug Safety
|October 6, 2010
PubMed
Summary
This summary is machine-generated.

This study found that gabapentin does not increase suicide attempt risk in non-psychiatric patients. However, gabapentin use was associated with reduced suicide attempt rates in patients with psychiatric disorders.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 8, 2026

Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • The U.S. Food and Drug Administration (FDA) issued a class warning in 2008 regarding antiepileptic drugs and increased risks of suicidal thoughts and behavior.
  • Concerns exist regarding the potential for antiepileptic drugs to influence suicidal ideation and actions in patient populations.

Purpose of the Study:

  • To investigate whether the antiepileptic drug gabapentin is associated with an increased risk of suicide attempts.
  • To evaluate the safety profile of gabapentin concerning suicidal behavior across various patient indications.

Main Methods:

  • A pharmacoepidemiologic study design was employed, comparing suicide attempt rates before and after gabapentin prescription.
  • Utilized the PharMetrics medical claims database, analyzing a cohort of 131,178 patients with one year of data pre- and post-initial gabapentin prescription.
  • Included patients diagnosed with epilepsy, pain disorders, bipolar illness, major depressive disorder, schizophrenia, and other psychiatric disorders.

Main Results:

  • Overall, no significant difference in suicide attempt rates was observed before (3.48/1000 patient-years) versus after (3.45/1000 patient-years) gabapentin prescription.
  • In non-psychiatric populations, no drug effect on suicide attempt rates was detected.
  • Significant reductions in suicide attempt rates were observed in patients with bipolar disorder, major depressive disorder, and other psychiatric disorders. Person-time analysis showed an overall reduction in suicide attempt rates when on gabapentin (2.01/1000 PY) compared to off gabapentin (2.30/1000 PY).

Conclusions:

  • Gabapentin does not elevate the risk of suicide attempts in patients without psychiatric conditions.
  • Gabapentin use is linked to a decreased risk of suicide attempts among individuals diagnosed with psychiatric disorders.